Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 714-720

  Li, Xu Yuan ^a   Lin, Ying Cheng ^a   Huang, Wan Lan ^a   Hong, Chao Qun ^a   Chen, Jiong Yu ^a   You, Yan Jie ^a   Li, Wei Bing ^a  

^a CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Human nasopharyngeal carcinoma cell line; Invasion; Matrix metalloproteinases; Migration; Vascular endothelial growth factor; Zoledronic acid

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; VASCULOTROPIN; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; MMP2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CANCER INVASION; CELL ADHESION; CELL MOTION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

BLOTTING, WESTERN; BONE DENSITY CONSERVATION AGENTS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DIPHOSPHONATES; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMIDAZOLES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NASOPHARYNGEAL NEOPLASMS; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84866276635     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9904-1     Document Type: Article

References (30)

1. Mcderrmott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci. 2001;26: 82-92.
2. Arango BA, Castrellon AB, Perez CA, Raez LE, Santos ES. Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev Anticancer Ther. 2010;10: 377-86.
3. Caponigro F, Longo F, Ionna F, Perri F. Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 2010; 21:471-7.
4. Razak AR, et al. Nasopharyngeal carcinoma: the next challenges. Eur J Cancer. 2010;46:1967-78.
5. Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem. 2007;14:2126-35.
6. Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 2005;65:4971-4.
7. Winter MC, Holen I, Coleman RE. Exploring the anti-tumor activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34:453-75.
8. Gnant M, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-91.
9. Rack B, et al. Effect of zoledronate on persisting isolated tumor cells in patients with early breast cancer. Anticancer Res. 2010;30:1807-13.
10. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer. 2003;88:1631-40.
11. Hasmim M, Bieler G, Rüegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost. 2007;5:166-73.
12. Goffinet M, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer. 2006;6:60.
13. Boissier S, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949-54.
14. Ferretti G, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69:35-43.
15. Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482-6.
16. Facchini G, et al. Metronomic administration of zoledronic acid, taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther. 2010;10:6.
17. Aft R, et al. Effect of zoledronic acid on disseminated tumor cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol. 2010;11:421-8.
18. Ottewell PD, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008;14:4658-66.
19. Fabbri F, et al. Zoledronic acid increases docetaxel cytotoxicity through pMEK, Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 2008;6:43.
20. Giraudo E, Hanahan D. Zoledronia acid inhibit angiogenesis and impairs tumorigenesis in a mouse model of cervical carcinogenesis. Haematol Rep. 2006;2:39-41.
21. Bäckman U, Svensson A, Christofferson RH, Azarbayjani F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res. 2008;28:1551-7.
22. Soltau J, et al. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model. Anticancer Res. 2008;28:933-41.
23. Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180-91.
24. Karabulut B, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009;33:239-46.
25. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52-67.
26. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life. 2001;52:61-6.
27. Evans KD, Oberbauer AM. Alendronate inhibits VEGF expression in growth plate chondrocytes by acting on the mevalonate pathway. Open Orthop J. 2009;3:83-8.
28. Santini D, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007;13:4482-6.
29. Montague R, et al. Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of zoledronic acid in prostate cancer. Eur Urol. 2004;46:389-402.
30. Li YY, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 2008;59:180-91.